Moody’s Analytics and City, University of London Partner on UK and EU Commercial Real Estate Data Initiative
9.11.2020 12:00:00 EET | Business Wire | Press release
Moody’s Analytics announced today a new partnership with The Business School (formerly Cass) at City, University of London, to build a database of loan-level commercial real estate (CRE) information covering the UK and Europe. The initiative will extend the Business School’s UK CRE lending survey under the Moody’s Analytics Data Alliance framework.
The COVID-19 pandemic has disrupted CRE fundamentals and highlighted the need for greater clarity around market drivers across sectors and between geographies. By participating in this initiative, lenders and other market participants will benefit from access to aggregate industry data, for enhanced market clarity, as well as robust analytics for benchmarking.
“The City-Moody’s Analytics initiative offers the exciting prospect of granular data pooling across the commercial real estate finance market. This will improve market transparency and allow for more robust data-driven analysis, thus strengthening informed credit flows,” said Peter Cosmetatos, CEO of the Commercial Real Estate Finance Council Europe. “Industry leaders and the Bank of England have previously recognized the importance of loan-level data pooling—this market-led initiative could be an important step towards achieving it.”
The data will be aggregated as part of the Moody’s Analytics Data Alliance, a collaborative effort of leading financial institutions and Moody's Analytics to create the world's largest collection of credit risk data. It is one of the world’s largest and most comprehensive data consortia with participation from more than 120 of the world’s leading banks, insurers, asset managers, and multi-lateral development banks. This initiative expands the Moody’s Analytics US CRE data consortium, which comprises data on loans worth $588B+, in 105,000+ properties covering 361 metropolitan areas, to the UK and Europe.
“We are delighted to partner with The Business School at City, University of London to create this essential CRE resource in the UK and Europe, which aligns with our commitment to helping the CRE industry address fundamental shifts caused by the pandemic,” said Jacob Grotta, Head of Risk and Finance Solutions at Moody’s Analytics. “The aim of the Data Alliance is to provide institutions with high-quality data, robust analytics, and advanced modelling capabilities for managing credit risk throughout the cycle.”
Co-leading the initiative is Dr. Nicole Lux, Senior Research Fellow at The Business School (formerly Cass), University of London. With extensive experience in real estate data collection, Dr. Lux conducts the UK CRE lending survey, which has been gathering data from more than 100 participant firms for more than 20 years to produce a comprehensive record of CRE lending in the market. Dr. Lux will work with industry participants to gather the loan-level information on behalf of the City-Moody’s Analytics initiative in the UK.
“Moody’s Analytics brings a wealth of expertise in collecting and parsing CRE and credit data in the US market,” said Dr. Lux. “I’m looking forward to working with the Data Alliance to broaden the scope of our CRE lending survey to encompass loan-level data and create more powerful analytics and benchmarking for CRE market participants in Europe.”
Learn more about the Moody’s Analytics Data Alliance.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn.
Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,200 people worldwide and maintains a presence in 40 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005455/en/
Contact information
KATERINA SOUMILOVA
Moody’s Analytics Communications
+1.212.553.1177
Moody’s Analytics Media Relations
moodysanalytics.com
twitter.com/moodysanalytics
linkedin.com/company/moodysanalytics
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
MariaDB Launches into the Agentic Era with an Agent-Ready Platform and a Bold New Brand4.11.2026 15:00:00 EET | Press release
MariaDB plc, the Unified Open Database Platform for the Agentic Enterprise, today announced MariaDB Enterprise Platform 2027, a release that delivers 56% higher peak throughput¹, stronger resilience for multi-region deployments and faster ways to build and run AI agents. What began as an open source operational database now spans mission-critical transactions, real-time analytics, in-memory speed, AI tooling and multi-region scale on one unified platform. The new brand identity unveiled alongside it shows where the company is headed, powering the AI-driven enterprise with the world’s most trusted database platform. Every AI agent in production is betting that the data in front of it is true. In most enterprises, that data is spread across multiple operational databases, a warehouse, vector stores, ETL engines and caches, and every integration between them adds latency, sync lag and another point of failure. The pressure is about to multiply. IDC predicts that by 2027, G2000 [the world’
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom